

## ABOUT THE VACCINE ALLIANCE

Vaccines protect health,  
allowing children to go to  
school and grow up to  
become productive adults.

1.5 million children under  
five still lose their lives  
every year to diseases  
that could be prevented  
by vaccines.

Gavi exists to redress  
this inequity.



Gavi - Evelyn Hochstein

Immunisation is one of the most successful and cost-effective health investments in history. Children who are immunised are healthier and more likely to attend and do well at school, and to go on to become productive, healthy adults.

Despite this compelling evidence, 19.9 million children, mainly in lower-income countries, are still not fully protected with the most basic vaccines. More than one in five of all children who die before the age of five lose their lives to vaccine-preventable diseases.

Gavi, the Vaccine Alliance is a global partnership bringing together public and private sectors with the shared goal of creating equal access to vaccines for all children.

## OUR IMPACT

 700 million children immunised through Gavi support by the end of 2018, saving more than 10 million lives in the long term

 Vaccines available to developing countries at a fraction of the price paid in rich countries

 Over US\$ 150 billion generated through the economic benefits of preventing diseases

 Immunisation rates in the world's poorest countries at unprecedented high levels

 New vaccines reaching developing countries at almost the same time as rich countries

**EXIT** Fifteen countries fully self-financing all vaccines introduced with Gavi funding

## WHAT THE VACCINE ALLIANCE DOES

Gavi funds immunisation programmes in developing countries, where the vast majority of the world's unvaccinated children live. We also support the strengthening of health systems to help ensure vaccines reach people everywhere. From 2016 to 2020, we are helping countries to immunise 300 million children. This will save 5–6 million lives in the long term.

Our funding supports 13 vaccines, including the pentavalent vaccine (against diphtheria, tetanus, whooping cough, hepatitis B and *Haemophilus influenzae* type b, known as Hib) and vaccines against pneumococcal disease and rotavirus (the main causes of pneumonia and diarrhoea), polio, measles and human papillomavirus, which causes cervical cancer.



## HOW THE VACCINE ALLIANCE WORKS

All partners invest in the Gavi business model, and all are accountable for its results.

Donors make long-term commitments to support Gavi, giving developing countries the confidence to invest in their routine immunisation programmes and allowing manufacturers to plan new investments.

All Gavi-supported countries co-finance a share of their vaccine costs. As their economies grow, they increase their investment in immunisation and eventually sustain their own programmes.

The availability of long-term, predictable funding for immunisation coupled with aggregated country demand enables manufacturers to supply vaccines at more affordable prices.

The Vaccine Alliance also leverages the private sector through innovative finance mechanisms and new approaches:



The **International Finance Facility for Immunisation (IFFIm)** converts long-term donor commitments into immediately available cash for Gavi.



The **Advance Market Commitment (AMC)** has allowed close to 60 countries to introduce the pneumococcal vaccine in just nine years, at less than 5% of the public price in the USA.



The **Gavi Matching Fund** gives the business world a way to support immunisation by providing expertise, funding and technology.



**Innovation for Uptake, Scale and Equity in Immunisation (INFUSE)** helps countries to accelerate the introduction of cutting-edge technology to improve vaccine delivery.

## PARTNERS

Since 2000, Gavi's public-private partnership has combined the technical expertise of the development community with the business know-how of the private sector.



**WHO** regulates vaccines and supports country introductions, strengthening immunisation coverage and data quality.



**UNICEF** procures vaccines and supports countries in maintaining their cold chain, improving access and collecting data.



**The World Bank** helps pioneer innovative finance mechanisms like IFFIm and the AMC.



**Bill & Melinda Gates Foundation**, one of our founding partners, provides funding and expertise, pioneers innovative approaches and supports research and development of new vaccines.

**Implementing country governments** identify their immunisation needs, co-finance and implement vaccine programmes.

**Civil society organisations** help ensure vaccines reach every child.

**Vaccine and cold chain equipment manufacturers** make available affordable, quality vaccines and cold chain equipment for developing countries.

**Donor country governments** make long-term funding commitments.

**Private sector partners** contribute resources, expertise and innovation to help achieve our mission.

**Research agencies** help us generate the evidence base and communicate the value of vaccines.